Merck Enpatoran Enters Phase 3 Trial for Lupus Treatment
Darmstadt, Germany | April 30, 2026 Merck has announced the first patient dosing in its global Phase 3 ELOWEN...
immunology
Advertisement
Cue Biopharma Expands Anti-IgE Pipeline in $691M Deal
Boston, USA | April 30, 2026 Cue Biopharma has entered into a strategic licensing agreement with Ascendant Health Sciences...
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
TRexBio Advances TRB-061 Phase 1b Trial for Atopic Dermatitis
SOUTH SAN FRANCISCO, April 29, 2026 TRexBio, Inc. has announced that the first patient has been dosed in the...
AbbVie $1.4B Durham Campus to Boost US Drug Manufacturing
NORTH CHICAGO, Ill., April 22, 2026 AbbVie has announced a landmark $1.4 billion investment to establish a state-of-the-art pharmaceutical...
Advertisements
Regeneron & Sanofi Secure FDA Approval for Dupixent in Pediatric CSU
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
Astellas and Pfizer Gain FDA Priority Review for PADCEV Combo
TOKYO, Japan and NEW YORK, U.S., April 20, 2026 Astellas Pharma Inc. and Pfizer Inc. have announced that the...
Nektar Rezpegaldesleukin Shows 52-Week Alopecia Results
SAN FRANCISCO, April 20, 2026 Nektar Therapeutics has reported compelling 52-week topline results from the Phase 2b REZOLVE-AA trial,...
Spyre to Reveal SKYLINE UC Trial Results on April 13
Waltham, Massachusetts | April 10, 2026 Spyre Therapeutics Inc. has announced that it will report topline results from Part...
Fortitude Advances T-Cell Therapy for Axial Disease
WALTHAM, Massachusetts, United States, April 7, 2026 Fortitude Biomedicines, Inc. announced progress on its lead immunology program, a first-in-class...
Advertisement
